Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 10/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254179 | 0.78 | MAP3K14 (0.56) | CHEK1GSK3BFYNPIK3CAMTOR | |
| SCHEMBL12998305 | 0.76 | CHEK1 (0.54) | CHEK1GSK3BFYNPIK3CAMTOR | |
| SCHEMBL3784431 | 0.75 | KDR (0.46) | FYNKDR | |
| SCHEMBL13745894 | 0.74 | CISD1 (0.59) | GSK3BPIK3CAMTOR | |
| SCHEMBL4250156 | 0.73 | CISD1 (0.58) | GSK3BPIK3CAMTOR | |
| SCHEMBL4250160 | 0.73 | CISD1 (0.58) | GSK3BPIK3CAMTOR | |
| SCHEMBL13745783 | 0.72 | TGFBR1 (0.40) | — | |
| SCHEMBL16331721 | 0.70 | CHEK1 (0.61) | CHEK1GSK3BFYNPIK3CAMTOR | |
| SCHEMBL4260578 | 0.70 | PIK3CA (0.46) | CHEK1PIK3CAMTOR | |
| SCHEMBL18609486 | 0.70 | MKNK1 (0.57) | CHEK1GSK3BFYNPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | CHEK1 553/4885GSK3B 398/4885FYN 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.